近日，北京律師張曉玲稱“在愛康國賓體檢10年未能查出患癌風險”一事引發廣泛關注。
A dispute between a Beijing lawyer and one of China's largest private health screening providers, iKang Guobin Healthcare Group, has ignited a heated public debate over the reliability of commercial medical check-ups in detecting serious illnesses.
The controversy began when Zhang Xiaoling, a practicing lawyer in Beijing, publicly accused iKang Guobin of failing to identify her cancer risk through annual physical examinations conducted over the past decade.
7月30日上午，愛康國賓召開“媒體說明會”。
愛康國賓相關負責人介紹了張女士在愛康近十年體檢的經過，該負責人稱張女士的體檢十年均為北京律師協會提供的福利基礎套餐。除2017年外，張女士沒有自費購買任何特色/升級專案。
In response, iKang Guobin held a press conference on Wednesday to present its defense. Company executives revealed that Zhang had consistently opted for basic check-up packages subsidized by the Beijing Lawyers Association (BLA) throughout her ten years as a client, with only one optional upgrade in 2017.
據介紹：
張女士2023年10月9日在北京愛康國賓西內門診部參加健康體檢，體檢結果顯示有腎錯構瘤可能，愛康國賓建議“首次發現者需要做CT，以除外其他腎臟佔位性病變”，“以除外其他腎臟佔位性病變”即是提示癌症可能性。
會上，愛康國賓還公佈了張女士2023年10月9日在北京愛康國賓西內門診部參加體檢的部分報告，其中專家建議與指導部分顯示：腎鈣化灶和腎錯構瘤可能。
The company displayed her 2023 medical report, which noted a suspected renal hamartoma and explicitly recommended further CT scans to rule out malignancies—a suggestion they claimed she did not pursue.
該負責人稱，不存在健康愛康體檢沒查出來異常，而其他機構就查出來的情況；根據現有的公開資訊，北京大學國際醫院病理報告明確標註張女士是早期腎癌，而不是其自述的晚期。
The company strongly denied allegations of negligence, citing a Peking University Internatoinal Hospital pathology report that classified Zhang's condition as early-stage kidney cancer rather than the advanced case she described.
愛康集團資深副總裁周曉江宣佈，已向法院提起訴訟，法院已正式立案受理。愛康集團董事長張黎剛表示，為了維護愛康15000名員工的尊嚴，為了給行業正名，愛康不得不做出這個非常艱難的決定。
Zhou Xiaojiang, iKang's senior vice president, announced the company had filed a defamation lawsuit against Zhang to "protect the reputation of its 15,000 employees" and "clarify industry standards."
Zhang later countered on social media that she had not been served any legal documents.
在說明會前一天，張曉玲透過微博釋出了愛康國賓“北京媒體見面會”10個謊言，稱自己不出意外地被排除出邀請名單之列。她將徵集20名關於體檢行業漏診、誤診行為的維權律師團隊，並在全國徵集1萬名愛康國賓體檢受害人的典型案例，正式發起公益訴訟，推動中國體檢醫療行業的立法完善。
The case has sparked broader discussions about the role and limitations of private health screenings. Zhang has pledged to form a legal team to pursue collective action on behalf of what she describes as victims of iKang's services, with the long-term goal of pushing for legislative reforms in China’s medical check-up industry.
據此前報道，7月17日，北京執業律師張曉玲表示，自己在愛康國賓做了10年體檢，但體檢報告始終無癌症預警。2024年，她被診斷出右腎癌症；2025年，癌細胞伴隨骨轉移。張曉玲質疑愛康國賓多年來實施假體檢，並向該機構發律師函。
Zhang, who was diagnosed with kidney cancer in 2024 and later found to have bone metastases in 2025, claimed the company had provided "fake check-ups".
在釋出會上，愛康集團創始人、董事長兼CEO張黎剛稱：“當你指望說，一個幾百塊錢的體檢能幫你什麼病都查出來，而要查單一的病，多花幾千幾萬塊錢的時候，你認為這樣的情況存在嗎？”
“至於（大眾對於體檢理解）這樣模糊的原因，就是因為我們公眾對於體檢與看病，沒有明確的邊界，導致公眾對體檢有很多誤解。”
Meanwhile, iKang CEO Zhang Ligang emphasized that basic check-ups should not be mistaken for comprehensive diagnostics. "Expecting a routine physical exam costing a few hundred yuan to detect all potential diseases is medically unrealistic," he stated during the press conference.
釋出會上，張黎剛還提到，體檢還不能預測所有的癌症，也無法取代專科醫生來看病，體檢的意義在於透過科學的檢查專案，幫助其發現身體可能的警報訊號，然後給出進一步診斷的建議，及時去找專科醫生做更為深入的檢查。
相關言論一齣引發不少網友熱議：
愛康國賓官方賬戶則在評論區留言：
據澎湃新聞評論稱，事實上，為了營銷，各種體檢機構可能會有意無意誇大體檢對於疾病早發現的效果，這其實為後續產生矛盾埋下了隱患。
說到底，體檢機構應該讓大家知道，健康體檢是一種過濾式的篩查，可以發現一些早期疾病，但不是發現早期疾病的“萬能保險”，大家對健康體檢不要期望過高。
Industry observers note the controversy reflects growing public skepticism toward private healthcare providers, many of which have been accused of overstating the effectiveness of early detection services in marketing campaigns.
此外，體檢的質量標準也要跟上，包括體檢結果的綜合評估、體檢套餐的合理搭配等。前端設計明瞭，消費者才能知道自己選擇的體檢，到底能帶給自己什麼。
Legal experts suggest the case could set important precedents for consumer rights and corporate accountability in China's rapidly expanding preventive healthcare sector.
你怎麼看？
來源：中國青年報 澎湃新聞 東方財經 讀秒財經等
推 薦 閱 讀